SCHEMBL15922260

SCHEMBL15922260

COc1cc(I)c(C(F)(F)F)cn1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
MAPT P10636 1/20 0.39
GAA P10253 3/20 0.38
NPSR1 Q6W5P4 1/20 0.38
CFTR P13569 1/20 0.37
CYP11B2 P19099 1/20 0.37
SLC22A12 Q96S37 1/20 0.37
POLB P06746 1/20 0.36
MCOLN3 Q8TDD5 1/20 0.36
MAPK3 P27361 5/20 0.35
AURKA O14965 2/20 0.35
KDR P35968 2/20 0.35
AURKB Q96GD4 2/20 0.35
MAPK1 P28482 1/20 0.35
LRRK2 Q5S007 1/20 0.35
NNMT P40261 1/20 0.34
MAPK10 P53779 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30340520 1.00 MEN1 (0.40) MEN1KMT2AMAPTGAANPSR1
SCHEMBL8429223 0.79 NNMT (0.46) MEN1KMT2AMAPTGAANPSR1
SCHEMBL16116125 0.76 MAPT (0.40) MEN1KMT2AMAPTGAANPSR1
SCHEMBL21027835 0.76 MEN1 (0.47) MEN1KMT2AMAPTGAANPSR1
SCHEMBL29953242 0.75 MEN1 (0.41) MEN1KMT2AMAPTGAANPSR1
SCHEMBL16115971 0.75 MEN1 (0.41) MEN1KMT2AMAPTGAANPSR1
SCHEMBL15923697 0.75 MEN1 (0.35) MEN1KMT2AMAPTGAANPSR1
SCHEMBL16629013 0.75 NNMT (0.37) MEN1KMT2AMAPTNNMT
SCHEMBL16656835 0.75 HPGD (0.35) CFTRSLC22A12LRRK2
SCHEMBL28682675 0.75 ASPH (0.34) CFTRCYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116113635-A Spiro compounds as melanocortin 4 receptor antagonists and uses thereof 辉瑞公司 2023-05-12 CN disclosed
EP-2934538-B1 FACTOR IXA INHIBITORS MERCK SHARP & DOHME (US) 2021-03-31 EP disclosed
US-9708308-B2 Factor IXa inhibitors MERCK SHARP DOHME CORP. (US) 2017-07-18 US disclosed
US-20150322056-A1 Factor IXa Inhibitors MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2015-11-12 US disclosed
EP-2934538-A1 FACTOR IXA INHIBITORS Merck Sharp & Dohme Corp. (US) 2015-10-28 EP disclosed
WO-2014120346-A1 FACTOR IXA INHIBITORS MERCK SHARP & DOHME CORP. (US) 2014-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150322056-A1 Factor IXa Inhibitors F9, F12, F8 MEN1 566/4885KMT2A 1201/4885MAPT 4751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.